MovDisordV3, Main, Merge, bibRecord, 005343

Effects of levodopa and COMT inhibitors on plasma Homocysteine in Parkinson's disease patients

Identifieur interne : 005343 ( Main/Merge ); précédent : 005342; suivant : 005344

Effects of levodopa and COMT inhibitors on plasma Homocysteine in Parkinson's disease patients

Auteurs : Paolo Lamberti [Italie] ; Stefano Zoccolella [Italie] ; Giovanni Iliceto [Italie] ; Elio Armenise [Italie] ; Angela Fraddosio [Italie] ; Michele De Mari [Italie] ; Paolo Livrea [Italie]

Source :

Movement disorders [ 0885-3185 ] ; 2005.

RBID : Pascal:05-0173268

Descripteurs français

Pascal (Inist)
- Système nerveux pathologie, Lévodopa, Homocystéine, Parkinson maladie, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Homocystein, Human, Levodopa, Nervous system diseases, Parkinson disease.

Abstract

Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). The mechanism underlying HHcy in PD is the O-methylation of levodopa catalyzed by catechol-O-methyltransferase (COMT) that produces S-adenosylhomocysteine, which is hydrolyzed rapidly to Hcy. COMT inhibitors (COMT-I) are used currently in the treatment of PD; however, no study has assessed the effects of COMT-I administration on Hcy concentrations in PD patients. We compared plasma levels of Hcy, B12, and folate in 26 PD patients treated with levodopa, 20 PD patients treated with levodopa + COMT-I, and 32 controls. No significant differences were found in vitamin B12 levels, whereas folate concentrations were significantly lower in the levodopa-treated group. Plasma Hcy was increased significantly in the two groups of PD patients and was significantly lower in the group treated with levodopa + COMT-I. Statistical analysis showed that the difference in mean Hcy levels observed among PD patients was related to the addition of COMT-I, rather than to folate concentrations. We conclude that levodopa treatment increases plasma Hcy and the addition of COMT-I effectively reduces HHcy.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 001F44
to stream PascalFrancis, to step Curation: 000D77
to stream PascalFrancis, to step Checkpoint: 001E65

Links to Exploration step

Pascal:05-0173268

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of levodopa and COMT inhibitors on plasma Homocysteine in Parkinson's disease patients</title>
<author><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zoccolella, Stefano" sort="Zoccolella, Stefano" uniqKey="Zoccolella S" first="Stefano" last="Zoccolella">Stefano Zoccolella</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Iliceto, Giovanni" sort="Iliceto, Giovanni" uniqKey="Iliceto G" first="Giovanni" last="Iliceto">Giovanni Iliceto</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Armenise, Elio" sort="Armenise, Elio" uniqKey="Armenise E" first="Elio" last="Armenise">Elio Armenise</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Internal Medicine and Public Health-Hygiene Section, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fraddosio, Angela" sort="Fraddosio, Angela" uniqKey="Fraddosio A" first="Angela" last="Fraddosio">Angela Fraddosio</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Mari, Michele" sort="De Mari, Michele" uniqKey="De Mari M" first="Michele" last="De Mari">Michele De Mari</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Livrea, Paolo" sort="Livrea, Paolo" uniqKey="Livrea P" first="Paolo" last="Livrea">Paolo Livrea</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0173268</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0173268 INIST</idno>
<idno type="RBID">Pascal:05-0173268</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001F44</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000D77</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001E65</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Lamberti P:effects:of:levodopa</idno>
<idno type="wicri:Area/Main/Merge">005343</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of levodopa and COMT inhibitors on plasma Homocysteine in Parkinson's disease patients</title>
<author><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zoccolella, Stefano" sort="Zoccolella, Stefano" uniqKey="Zoccolella S" first="Stefano" last="Zoccolella">Stefano Zoccolella</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Iliceto, Giovanni" sort="Iliceto, Giovanni" uniqKey="Iliceto G" first="Giovanni" last="Iliceto">Giovanni Iliceto</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Armenise, Elio" sort="Armenise, Elio" uniqKey="Armenise E" first="Elio" last="Armenise">Elio Armenise</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Internal Medicine and Public Health-Hygiene Section, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Fraddosio, Angela" sort="Fraddosio, Angela" uniqKey="Fraddosio A" first="Angela" last="Fraddosio">Angela Fraddosio</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Mari, Michele" sort="De Mari, Michele" uniqKey="De Mari M" first="Michele" last="De Mari">Michele De Mari</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Livrea, Paolo" sort="Livrea, Paolo" uniqKey="Livrea P" first="Paolo" last="Livrea">Paolo Livrea</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, University of Bari</s1>
<s2>Bari</s2>
<s3>ITA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>Bari</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Homocystein</term>
<term>Human</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Lévodopa</term>
<term>Homocystéine</term>
<term>Parkinson maladie</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment, and dementia. Elevated plasma concentrations of Hcy have been found recently in Parkinson's disease (PD) patients treated with levodopa, suggesting that levodopa is a cause of hyperhomocysteinemia (HHcy). The mechanism underlying HHcy in PD is the O-methylation of levodopa catalyzed by catechol-O-methyltransferase (COMT) that produces S-adenosylhomocysteine, which is hydrolyzed rapidly to Hcy. COMT inhibitors (COMT-I) are used currently in the treatment of PD; however, no study has assessed the effects of COMT-I administration on Hcy concentrations in PD patients. We compared plasma levels of Hcy, B12, and folate in 26 PD patients treated with levodopa, 20 PD patients treated with levodopa + COMT-I, and 32 controls. No significant differences were found in vitamin B12 levels, whereas folate concentrations were significantly lower in the levodopa-treated group. Plasma Hcy was increased significantly in the two groups of PD patients and was significantly lower in the group treated with levodopa + COMT-I. Statistical analysis showed that the difference in mean Hcy levels observed among PD patients was related to the addition of COMT-I, rather than to folate concentrations. We conclude that levodopa treatment increases plasma Hcy and the addition of COMT-I effectively reduces HHcy.</div>
</front>
</TEI>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name>
</noRegion>
<name sortKey="Armenise, Elio" sort="Armenise, Elio" uniqKey="Armenise E" first="Elio" last="Armenise">Elio Armenise</name>
<name sortKey="De Mari, Michele" sort="De Mari, Michele" uniqKey="De Mari M" first="Michele" last="De Mari">Michele De Mari</name>
<name sortKey="Fraddosio, Angela" sort="Fraddosio, Angela" uniqKey="Fraddosio A" first="Angela" last="Fraddosio">Angela Fraddosio</name>
<name sortKey="Iliceto, Giovanni" sort="Iliceto, Giovanni" uniqKey="Iliceto G" first="Giovanni" last="Iliceto">Giovanni Iliceto</name>
<name sortKey="Livrea, Paolo" sort="Livrea, Paolo" uniqKey="Livrea P" first="Paolo" last="Livrea">Paolo Livrea</name>
<name sortKey="Zoccolella, Stefano" sort="Zoccolella, Stefano" uniqKey="Zoccolella S" first="Stefano" last="Zoccolella">Stefano Zoccolella</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005343 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005343 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     Pascal:05-0173268
   |texte=   Effects of levodopa and COMT inhibitors on plasma Homocysteine in Parkinson's disease patients
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Effects of levodopa and COMT inhibitors on plasma Homocysteine in Parkinson's disease patients

Effects of levodopa and COMT inhibitors on plasma Homocysteine in Parkinson's disease patients

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri